Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice

Details

Serval ID
serval:BIB_E925A77511CE
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice
Journal
Lung Cancer
Author(s)
Mattson  K., Bosquee  L., Dabouis  G., Le Groumellec  A., Pujol  J. L., Marien  S., Stupp  R., Douillard  J. Y., Bragas  B., Berille  J., Olivares  R., Le Chevalier  T.
ISSN
0169-5002 (Print)
Publication state
Published
Issued date
09/2000
Volume
29
Number
3
Pages
205-16
Notes
Clinical Trial
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Sep
Abstract
The purpose of this study was to evaluate the efficacy and safety of docetaxel as first- and second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) under routine clinical conditions. Two hundred and three patients with advanced NSCLC received docetaxel 100 mg/m2 (1-h intravenous infusion) every 3 weeks, with oral corticosteroid pre-medication, of whom 173 were eligible. Median age was 60 (29-78) years and median Karnofsky performance status was 80% (60-100). A total of 77% of patients had metastatic disease, 33% had bone metastases and 18% had liver metastases. The treatment was second-line or more for 72 patients (35%). Overall response rates in the eligible population were 19.7% [95% CI, 12.5-23.0] for both treatments, 22.6% for first-line treatment and 13.8% for second-line treatment. Median survival was 8.3 months and 1-year survival was 35% for the overall population (8.7 months and 38%, respectively, for patients receiving first-line treatment and 7.2 months and 27%, respectively, for patients receiving second-line treatment). Neutropenia, grade 3 and 4, occurred in 57% of the cycles and 5% of patients experienced febrile neutropenia. Alopecia (62% of patients), neuro-sensory symptoms (32%), asthenia (28%), diarrhea (22%), nausea (22%) and nail disorders (20%) were the most common non-hematological adverse effects. A total of 33% of patients suffered fluid retention, despite the use of corticosteroid pre-medication, but this was only severe in 1.5% of patients. It was possible to confirm the efficacy of docetaxel as a single agent for first- and second-line chemotherapy in a large patient population treated in a community setting.
Keywords
Adult Aged Antineoplastic Agents, Phytogenic/adverse effects/*therapeutic use Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology Female Humans Lung Neoplasms/*drug therapy/pathology Male Middle Aged Paclitaxel/adverse effects/*analogs & derivatives/therapeutic use Survival Analysis *Taxoids Treatment Outcome
Pubmed
Web of science
Create date
28/01/2008 8:39
Last modification date
20/08/2019 16:11
Usage data